EUCTR2017-004377-13-ES进行中（未招募）1 期
A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer. - PROSTRATEGY
SOGUG (Spanish Genitourinary Oncologic Group)0 个研究点目标入组 120 人开始时间: 2018年10月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patients must be at least 18 years of age
- •2. Signed and dated written informed consent, obtained before the performance of any protocol-related procedure.
- •3. Histological or cytological diagnosis of prostate cancer with an elevated PSA level and radiologic evidence of metastatic disease.
- •4. ECOG performance-status score of 0, 1, or 2. Patients with a score of 2 are eligible if the decrement in functioning was due to prostate cancer.
- •5. Metastatic disease that has spread beyond the prostate or relapsed after local therapy, documented by body CT scan and/or bone scan, according to PCWG 3 criteria, with high
- •volume according to criteria used in the CHAARTED study.
- •6. Radiological and scintigraphic studies to identify initial evaluable disease should be done as follows:
- •If ADT has not been initiated, CT scans and bone scan must be obtained within 6 weeks prior to the start of ADT.
- •If all required imaging had not been completed prior to starting ADT, any additional scan must be obtained after starting androgen deprivation but prior to randomization and the initiation of docetaxel (It is assumed that the scans of patients with high volume disease would not normalize in less than 120 days to the point that a patient would go from high volume” to low volume”).
- •7. Measurable or evaluable disease according to the PWGC 3.
- •8. Patients who started ADT for metastatic disease are eligible if ADT commenced within 120 days before randomization, they have not started docetaxel chemotherapy yet, and there was
- •no evidence of clinical, radiological or biochemical progression after ADT.
- •9. Patients receiving ADT in the adjuvant and/or neoadjuvant setting for less than 30 months of therapy, AND the effect of the last depot injection had expired at least 12 months prior to
- •documentation of metastatic disease, AND
- •They had no evidence of disease (PSA < 0.2 ng/dL) after prostatectomy plus hormonal therapy, or
- •PSA was < 0.5 ng/dL after completing radiation therapy plus adjuvant or neoadjuvant hormonal therapy, and had not doubled above nadir in at least 12 months.
- •10. Patients must have adequate organ function within 4 weeks prior to randomization and evidenced by:
- •Absolute Neutrophil Count > 1500/mm 3
- •Platelet count > 100,000/mm 3
- •Creatinine clearance (CrCl)> 30 mL/min calculated at screening using the Cockcroft- Gault formula: Creatinine clearance for mule (mL/min) = (140- age in years)(body weight in kg)/[72x(serum creatinine in mg/dl).
- •Total bilirubin < 1.5 ULN (< 3.0 mg/dl in patients with Gilbert´s Syndrome).
- •Prothrombin time or INR and PTT < 1.5 x ULN, except if on therapeutic anti- coagulation in which case the patient can be enrolled if stable and anti-coagulation levels are appropriate for their condition per good clinical practice.
- •ALT and AST < or = 3 x ULN (or < or = 5 if liver metastases)
- •11. At least 4 weeks should have passed after major surgery prior to randomization, and the patient should be recovered from all side effects and complications.
- •12. Men who are sexually active with WOCBP must agree to follow instructions for methods of contraception for the duration of treatment with study drug plus 5 half-lives of study drug plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
排除标准
- •1. Patients are not eligible if the PSA has risen from its lowest point, between the beginning of androgen deprivation therapy and the date of randomization, and met criteria for progression as defined in the protocol.
- •2. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, PROSTVAC, Sipuleucel-T or any previous immunotherapy or vaccines for cancer.
- •3. Prior chemotherapy in the adjuvant or neoadjuvant setting.
- •4. Unable to receive docetaxel at full doses at investigator criteria.
- •5. Peripheral neuropathy grade > 1.
- •6. All toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia or fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug. Subjects with toxicities attributed to prior surgery or radiotherapy, which are not expected to resolve and result in long-term lasting sequelae, are permitted to enrol.
- •7. History of hypersensitivity reaction to Docetaxel®, other drugs formulated with polysorbate 80, or monoclonal antibodies.
- •8. Prior hormone therapy or immunotherapy in the metastatic setting.
- •9. Prior palliative radiation therapy within 30 days of starting docetaxel.
- •10. Known acute or chronic HIV, Hepatitis B, or Hepatitis C. Past Hepatitis B infection with no signs of activity later, are allowed
- •11. Active brain metastases or leptomeningeal metastases, except if they have been treated and there is a magnetic resonance imaging (or CT scan if MRI were contraindicated) showing no evidence of progression for at least 4 weeks after the treatment
- •12. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days previous to randomization. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •13. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are allowed.
- •14. Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within the previous six months
- •15. History of malignancy in the past 5 years except for basal cell and squamous cell carcinoma of the skin and non-muscle-invasive bladder cancer. Other more malignancies considered to have a low potential to progress may be enrolled if approved by study chair.
- •16. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
- •17. Participation in another clinical trial within 30 days prior to randomization.
研究者
相似试验
进行中（未招募）
1 期
Multidisciplinar, multicenter, randomized phase III clinical trial comparing taxotere plus estramustine phosphate plus prednisone, versus taxotere prednisone, in advanced prostate carcinoma patients with biochemical relapse during androgen ablation.Acvanced prostate carcinomaEUCTR2004-003885-14-ESAventis Pharma, S.A.172
进行中（未招募）
不适用
Phase II, randomized, double arm, multi-center study evaluating the efficacy and safety of azithromycin for the long term prophylactic treatment of COPD in primary antibody deficiency patients with clinical and spirometrically confirmed COPD suffering from repeated acute exacerbationsprimary immunodefciency patients with COPD and frequent exacerbationsMedDRA version: 14.1Level: LLTClassification code 10029978Term: Obstructive chronic bronchitis with acute exacerbationSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10013289Term: Disorders involving the immune mechanismSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.1Level: LLTClassification code 10003554Term: Asthma aggravatedSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004351-39-ITAZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
进行中（未招募）
不适用
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute ischemic strokeEUCTR2008-003397-17-NLMitsubishi Tanabe Pharma Corporation
进行中（未招募）
不适用
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute ischemic strokeMedDRA version: 9.1Level: LLTClassification code 10055221Term: Ischemic strokeEUCTR2008-003397-17-GBMitsubishi Tanabe Pharma Corporation36
已完成
2 期
A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI-186 in subjects with acute ischemic strokeAcute Ischemic Stroke (AIS) - stroke10011954NL-OMON35656Mitsubishi Pharma Corporation12